Get the Stockscreener App
7.14
4.42%
-0.33
After Hours:
7.25
0.11
+1.54%
Mersana Therapeutics Inc stock is traded at $7.14, with a volume of 27,266.
It is down -4.42% in the last 24 hours and up +17.63% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
See More
Previous Close:
$7.47
Open:
$7.31
24h Volume:
27,266
Relative Volume:
0.26
Market Cap:
$35.63M
Revenue:
$34.77M
Net Income/Loss:
$-74.04M
P/E Ratio:
-0.9038
EPS:
-7.9
Net Cash Flow:
$-79.76M
1W Performance:
+4.69%
1M Performance:
+17.63%
6M Performance:
-44.03%
1Y Performance:
-83.86%
1-Day Range:
$7.13
$7.455
1-Week Range:
$6.6319
$7.70
52-Week Range:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
7.14 | 36.68M | 34.77M | -74.04M | -79.76M | -7.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | William Blair | Outperform |
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Price Action Confirms Reversal in Mersana Therapeutics Inc. TrendJuly 2025 Patterns & Weekly Top Performers Watchlists - beatles.ru
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High? - Yahoo Finance
Mersana Therapeutics Inc. Recovers — But Is It SustainableJuly 2025 Price Swings & Low Risk High Win Rate Stock Picks - beatles.ru
Can Mersana Therapeutics Inc. reach resistance levels soonQuarterly Trade Review & AI Powered Market Trend Analysis - beatles.ru
Mersana Therapeutics Faces Nasdaq Non-Compliance Notice - MSN
Can Mersana Therapeutics Inc. stock double in the next year2025 Institutional Moves & Daily Market Momentum Tracking - خودرو بانک
Is Mersana Therapeutics Inc. stock forming a cup and handleJuly 2025 Analyst Calls & Stock Portfolio Risk Management - خودرو بانک
Published on: 2025-09-05 14:49:22 - Newser
What does recent volatility data suggest for Mersana Therapeutics Inc.Trade Entry Summary & Fast Gain Stock Trading Tips - Newser
How sentiment analysis helps forecast Mersana Therapeutics Inc.2025 Trading Recap & Risk Controlled Stock Alerts - Newser
Can Mersana Therapeutics Inc. deliver alphaJuly 2025 Sector Moves & Technical Buy Zone Confirmation - خودرو بانک
Key resistance and support levels for Mersana Therapeutics Inc.Quarterly Performance Summary & Daily Market Momentum Tracking - Newser
Using Bollinger Bands to evaluate Mersana Therapeutics Inc.Weekly Trade Summary & Real-Time Buy Signal Notifications - Newser
Published on: 2025-09-05 05:23:37 - Newser
What Fibonacci levels say about Mersana Therapeutics Inc. reboundJuly 2025 Breakouts & Weekly Setup with High ROI Potential - Newser
What data driven models say about Mersana Therapeutics Inc.’s futureAnalyst Downgrade & Safe Swing Trade Setup Alerts - Newser
Mersana Therapeutics Inc. recovery potential after sell offQuarterly Profit Report & Long-Term Investment Growth Plans - Newser
Mersana Therapeutics’ Earnings Call Highlights Progress and Challenges - MSN
How sensitive is Mersana Therapeutics Inc. to inflation2025 Winners & Losers & AI Powered Trade Plan Recommendations - خودرو بانک
Is Mersana Therapeutics Inc. reversing from oversold territoryMarket Performance Report & Real-Time Market Sentiment Alerts - Newser
How volatile is Mersana Therapeutics Inc. stockWeekly Trade Report & Long Hold Capital Preservation Tips - خودرو بانک
Will Mersana Therapeutics Inc. face regulatory challengesJuly 2025 Drop Watch & Reliable Breakout Stock Forecasts - khodrobank.com
Is Mersana Therapeutics Inc. stock reversal real or fake2025 EndofYear Setup & Risk Managed Investment Signals - Newser
Will Mersana Therapeutics Inc. outperform the marketStop Loss & High Accuracy Swing Entry Alerts - Newser
Is Mersana Therapeutics Inc. a top pick in the sectorDividend Hike & Weekly Market Pulse Updates - خودرو بانک
Has Mersana Therapeutics Inc. formed a bullish divergenceMarket Risk Summary & Proven Capital Preservation Methods - Newser
Best data tools to analyze Mersana Therapeutics Inc. stockMarket Volume Summary & Low Risk Entry Point Guides - Newser
Evaluating Mersana Therapeutics Inc. with trendline analysisRisk Management & Risk Managed Trade Strategies - Newser
Leading vs lagging indicators on Mersana Therapeutics Inc. performanceJuly 2025 Analyst Calls & Weekly High Momentum Picks - Newser
Analyzing net buyer seller activity in Mersana Therapeutics Inc.July 2025 Technicals & Verified Momentum Stock Alerts - Newser
What recovery options are there for Mersana Therapeutics Inc.2025 Technical Overview & Verified Trade Idea Suggestions - Newser
Will Mersana Therapeutics Inc. bounce back from current support2025 Technical Overview & Accurate Intraday Trade Tips - Newser
How moving averages guide Mersana Therapeutics Inc. tradingWeekly Stock Report & Risk Controlled Swing Alerts - Newser
Using Python tools to backtest Mersana Therapeutics Inc. strategiesAnalyst Upgrade & Weekly Return Optimization Plans - Newser
Using data tools to time your Mersana Therapeutics Inc. exitEarnings Growth Report & Entry Point Confirmation Alerts - Newser
Can Mersana Therapeutics Inc. generate free cash flowJuly 2025 Summary & Consistent Return Strategy Ideas - خودرو بانک
Sector ETF performance correlation with Mersana Therapeutics Inc.Options Play & High Win Rate Trade Tips - Newser
Can momentum traders help lift Mersana Therapeutics Inc.2025 Market Sentiment & Stepwise Entry/Exit Trade Alerts - Newser
Ranking Mersana Therapeutics Inc. among high performing stocks via toolsWeekly Trend Report & Weekly Setup with ROI Potential - Newser
Chart based exit strategy for Mersana Therapeutics Inc.2025 Market Outlook & Real-Time Buy Zone Alerts - Newser
Is now a turning point for Mersana Therapeutics Inc.Trade Exit Summary & High Return Trade Opportunity Guides - Newser
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):